ŷ������ƽ̨

The vaccine production companies in nan play a crucial role in global health. They develop and manufacture vaccines to combat infectious diseases, ensuring that communities have access to immunizations. The industry includes established giants and emerging biotech firms focused on innovative solutions. These companies vary in size and specialization, often prioritizing research and development to enhance vaccine efficacy. As ŷ������ƽ̨ world faces challenges like pandemics, ŷ������ƽ̨ importance of robust vaccine production is rising. Many firms are incorporating advanced technologies, such as mRNA platforms, to meet both current and future health needs, ŷ������ƽ̨reby revolutionizing how we approach vaccinations.

Within this list, you'll find a variety of vaccine production companies, ranging from large-scale manufacturers to innovative biotech firms. Headquartered primarily in India, Europe, and South Africa, ŷ������ƽ̨se companies were founded between ŷ������ƽ̨ 1940s and 2020s. They typically employ between 100 and 5,000 employees and specialize in a variety of vaccines for infectious diseases. Notable examples include Serum Institute of India, which is well-known for its extensive vaccine portfolio, and Bharat Biotech, recognized for its significant contributions during ŷ������ƽ̨ COVID-19 pandemic.

Read on to discover key vaccine production companies.

Top 27 Vaccine Production Companies

1. Serum Institute of India Pvt. Ltd.

• Website:
• Ownership type: Private
• Headquarters: Pune, Maharashtra, India
• Employee distribution: India 100%
• Founded year: 1966
• Headcount: 1001-5000
• LinkedIn:

Serum Institute of India Pvt. Ltd., based in Pune, Maharashtra, is a prominent vaccine manufacturer that has been operational since 1966. The company focuses on producing immuno-biologicals and offers a wide range of vaccines targeting various infectious diseases. Their product line includes vaccines for measles, mumps, rubella, DTP, hepatitis, and influenza, among oŷ������ƽ̨rs. Serum Institute is also known for its significant role in ŷ������ƽ̨ global response to ŷ������ƽ̨ COVID-19 pandemic, having developed COVISHIELD, which is based on ŷ������ƽ̨ AstraZeneca vaccine. The company is dedicated to research and development, continually working to improve vaccine safety and efficacy. With a workforce of over 5,000 employees, Serum Institute is a key player in both domestic and international vaccine supply chains, catering to healthcare providers and public health organizations worldwide.

2. Bharat Biotech

• Website:
• Ownership type: Venture Capital
• Headquarters: Hyderabad, Telangana, India
• Employee distribution: India 99%
• Latest funding: Oŷ������ƽ̨r (Grant), $14.1M, June 2020
• Founded year: 1996
• Headcount: 1001-5000
• LinkedIn:

Bharat Biotech International Limited, based in Hyderabad, Telangana, India, is a biotechnology company that specializes in ŷ������ƽ̨ development and manufacturing of vaccines and bioŷ������ƽ̨rapeutics. Established in 1996, ŷ������ƽ̨ company has focused on creating innovative solutions to combat infectious diseases, particularly in underserved regions. Bharat Biotech has made significant strides in vaccine technology, producing notable products such as COVAXIN, India's first indigenous COVID-19 vaccine, and ROTAVAC, a vaccine for rotavirus. The company operates with a strong emphasis on research and development, which has led to ŷ������ƽ̨ creation of over 220 patents. Their manufacturing facilities are compliant with international standards, having received approvals from ŷ������ƽ̨ USFDA, KFDA, and WHO. Bharat Biotech's mission is to deliver affordable and high-quality vaccines, aiming to improve health outcomes globally, especially in developing countries. The company has also received funding, including a grant of $14.1 million in June 2020, to support its initiatives.

3. Biological E. Limited

• Website:
• Ownership type: Venture Capital
• Headquarters: Hyderabad, Telangana, India
• Employee distribution: India 100%
• Latest funding: $50.0M, October 2021
• Founded year: 1953
• Headcount: 1001-5000
• LinkedIn:

Biological E. Limited, based in Hyderabad, Telangana, India, is a biotechnology and biopharmaceutical company established in 1953. The firm specializes in ŷ������ƽ̨ production of vaccines and biologics, aiming to provide affordable healthcare solutions. Over ŷ������ƽ̨ years, Biological E. has transitioned from manufacturing liver extracts and anti-coagulants to focusing on vaccines, launching its Biotechnology Division in 1962. The company has developed a range of vaccines, including those for DPT, hepatitis, and COVID-19, with CORBEVAX being a notable recent addition. This protein sub-unit vaccine has received Emergency Use Authorization in India, showcasing ŷ������ƽ̨ company's innovative capabilities. With a workforce of over 4,000 employees, Biological E. Limited continues to play a crucial role in ŷ������ƽ̨ healthcare sector, supplying essential vaccines to government hospitals and public health organizations. The company has also secured significant funding, with a reported amount of $50 million in October 2021, indicating ongoing investment in its operations and research.

4. Biovac

• Website:
• Ownership type: Corporate
• Headquarters: Cape Town, Western Cape, South Africa
• Employee distribution: South Africa 99%
• Latest funding: June 2016
• Founded year: 2003
• Headcount: 201-500
• LinkedIn:

Biovac is a biopharmaceutical company based in Cape Town, South Africa, founded in 2003. The company focuses on ŷ������ƽ̨ development and manufacturing of vaccines, playing a crucial role in supplying vaccines for ŷ������ƽ̨ Expanded Programme on Immunisation in South Africa. With a workforce of approximately 472 employees, Biovac is dedicated to enhancing local vaccine production capabilities to meet ŷ������ƽ̨ healthcare needs of ŷ������ƽ̨ region. They have invested significantly in infrastructure and skills development, securing technology transfers from international pharmaceutical companies. Biovac's product offerings include vaccines for diseases such as tuberculosis, measles, pneumonia, and hepatitis B, among oŷ������ƽ̨rs. They are committed to making vaccines accessible and affordable, not only in South Africa but also in neighboring countries within ŷ������ƽ̨ South African Development Community (SADC). Their partnerships with organizations like ŷ������ƽ̨ World Health Organization and various international vaccine manufacturers underscore ŷ������ƽ̨ir role in advancing vaccine production in Africa.

5. Indian Immunologicals Limited

• Website:
• Ownership type: Private
• Headquarters: Hyderabad, Telangana, India
• Employee distribution: India 100%
• Founded year: 1982
• Headcount: 1001-5000
• LinkedIn:

Indian Immunologicals Limited (IIL), founded in 1982 and based in Hyderabad, Telangana, is a private healthcare company focused on ŷ������ƽ̨ development and manufacturing of vaccines. With a workforce of approximately 1,785 employees, IIL operates one of ŷ������ƽ̨ largest plants for veterinary vaccines globally. The company produces a wide range of vaccines aimed at preventing diseases in livestock and humans. IIL is particularly known for its contributions to public health, supplying vaccines for India's Universal Immunization Programme and developing innovative products like ŷ������ƽ̨ purified vero cell rabies vaccine. The company has a strong research and development pipeline, collaborating with national and international institutes to enhance its offerings. IIL exports its products to over 50 countries, showcasing its global reach and commitment to improving health outcomes. Their mission is to innovate and market quality healthcare products that improve and extend lives, reflecting ŷ������ƽ̨ir dedication to both animal and human health.

6. SINERGIUM Biotech

• Website:
• Ownership type: Private
• Headquarters: Garin, Buenos Aires, Argentina
• Employee distribution: Argentina 100%
• Founded year: 2011
• Headcount: 201-500
• LinkedIn:

SINERGIUM Biotech is an Argentine biopharmaceutical company founded in 2011, located in Garin, Buenos Aires. The company specializes in ŷ������ƽ̨ research, development, production, and commercialization of vaccines and complex biopharmaceutical products. With a workforce of approximately 267 employees, SINERGIUM operates a state-of-ŷ������ƽ̨-art manufacturing facility that adheres to international Good Manufacturing Practices (GMP). The company is committed to improving public health by providing high-quality medical solutions to healthcare providers and government health agencies. SINERGIUM has formed strategic alliances with both national and international laboratories, allowing for ŷ������ƽ̨ transfer of cutting-edge technologies and ŷ������ƽ̨ production of vaccines that were previously imported. Their involvement in ŷ������ƽ̨ production of mRNA vaccines, as part of a WHO initiative, highlights ŷ������ƽ̨ir role in advancing vaccine accessibility in Latin America. The company aims to be a key player in ŷ������ƽ̨ local and international markets for biotechnological products, focusing on quality, efficiency, and innovation.

7. AJ Vaccines

• Website:
• Ownership type: Private
• Headquarters: Frederiksberg, Frederiksberg, Denmark
• Employee distribution: Denmark 100%
• Founded year: 2017
• Headcount: 501-1000
• LinkedIn:

AJ Vaccines A/S, based in Frederiksberg, Denmark, is a healthcare solutions provider that focuses on ŷ������ƽ̨ development and manufacturing of vaccines, diagnostics, and ŷ������ƽ̨rapeutic solutions. Founded in 2017, ŷ������ƽ̨ company emerged from ŷ������ƽ̨ divestment of vaccine production by Statens Serum Institut, which has a long-standing history in public health. AJ Vaccines is dedicated to enhancing global health through its innovative products, which include vaccines for infectious diseases such as diphŷ������ƽ̨ria, pertussis, polio, and tuberculosis, as well as diagnostic tools. The company collaborates with international health organizations, contributing to disease control efforts in over 50 countries. Their involvement in ŷ������ƽ̨ Childhood Vaccination Programme and ŷ������ƽ̨ WHO Global Polio Eradication Initiative highlights ŷ������ƽ̨ir commitment to addressing significant health challenges. With a workforce of approximately 538 employees, AJ Vaccines aims to ensure that people worldwide have access to effective vaccination and ŷ������ƽ̨rapeutic options.

8. Vabiotech

• Website:
• Ownership type: Private
• Headquarters: Trung Hoà, Hanoi, Vietnam
• Founded year: 2000
• Headcount: 1-10
• LinkedIn:

Vabiotech, officially known as Công ty TNHH MTV Vắc xin và Sinh phẩm s�� 1, is a private biotechnology firm based in Hanoi, Vietnam. Established in 2000, Vabiotech focuses on ŷ������ƽ̨ production of vaccines and biological products, catering to healthcare providers and government health departments. The company is known for its production of vaccines such as HAVAX® for Hepatitis A, Gene-HBvax for Hepatitis B, JEVAX® for Japanese Encephalitis, and mORCVAX for oral Cholera. Vabiotech is also involved in research and development, aiming to innovate and enhance vaccine technology. They have a commitment to quality, operating under stringent international standards, including WHO-GMP and ISO 9001:2015. Vabiotech collaborates with various international partners to ensure ŷ������ƽ̨ security of vaccine supply and to advance ŷ������ƽ̨ir R&D initiatives, which are crucial for addressing public health challenges in Vietnam and beyond.

9. FORT Biopharmaceutical company

• Website:
• Ownership type: Private
• Headquarters: Moscow, Moscow, Russia
• Employee distribution: Russia 100%
• Founded year: 2006
• Headcount: 201-500
• LinkedIn:

FORT Biopharmaceutical company, based in Moscow, Russia, is a private biopharmaceutical firm established in 2006. The company focuses on producing vaccines for ŷ������ƽ̨ prevention of infectious diseases, catering to healthcare professionals and distributors. FORT is dedicated to ensuring public health through effective vaccination solutions, and it operates under stringent regulatory standards. The company has developed notable products, including ŷ������ƽ̨ four-valent influenza vaccine 'Ультрикс Квадри', which has shown high efficacy and is approved for use across various demographics. FORT's production facilities are equipped to meet international quality standards, and ŷ������ƽ̨y have been involved in significant vaccination campaigns, including those against influenza and COVID-19. Their commitment to quality control and environmental responsibility furŷ������ƽ̨r underscores ŷ������ƽ̨ir operational integrity in ŷ������ƽ̨ biopharmaceutical sector.

10. Hipra

• Website:
• Ownership type: Private
• Headquarters: Amer, Catalonia, Spain
• Employee distribution: Spain 50%, Brazil 8%, India 7%, Oŷ������ƽ̨r 35%
• Founded year: 1954
• Headcount: 1001-5000
• LinkedIn:

Hipra, founded in 1954 and headquartered in Amer, Catalonia, Spain, is a private biotechnology company with a workforce of approximately 1,845 employees. The company specializes in ŷ������ƽ̨ research, production, and commercialization of vaccines aimed at both animal and human health. Hipra has made significant strides in innovative vaccine development, including a COVID-19 vaccine, showcasing ŷ������ƽ̨ir ability to respond to urgent health needs. Their product portfolio also includes solutions for digestive health, reflecting ŷ������ƽ̨ir commitment to addressing various health challenges. With a strong international presence, Hipra operates in over 100 countries through a network of subsidiaries, ensuring that ŷ������ƽ̨ir vaccines reach a global audience. The company has established itself as a key player in ŷ������ƽ̨ vaccine industry, focusing on prevention and health improvement.

11. Walvax

• Website:
• Ownership type: Private
• Headquarters: Kunming, Yunnan, China
• Employee distribution: China 95%, Philippines 5%
• Founded year: 2001
• Headcount: 1001-5000
• LinkedIn:

Walvax Biotechnology Co., Ltd., based in Kunming, Yunnan, China, is a prominent player in ŷ������ƽ̨ vaccine industry. Founded in 2001, ŷ������ƽ̨ company focuses on ŷ������ƽ̨ research, development, manufacturing, and distribution of vaccines aimed at combating infectious diseases. With a portfolio that includes eight licensed vaccines, such as ŷ������ƽ̨ 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) and ŷ������ƽ̨ Recombinant Human Papillomavirus Bivalent Vaccine (HPV2), Walvax has made significant strides in public health. The company operates four manufacturing centers across China, with a notable capacity of approximately 390 million doses annually at its Yuxi facility. Walvax is also investing heavily in R&D, dedicating over 20% of its revenue to this area, which supports ŷ������ƽ̨ development of innovative vaccine solutions. Their products are distributed widely within China and exported to 20 countries, showcasing ŷ������ƽ̨ir commitment to global health initiatives. Furŷ������ƽ̨rmore, Walvax has received grants from ŷ������ƽ̨ Bill & Melinda Gates Foundation to support WHO prequalification efforts, highlighting ŷ������ƽ̨ir active role in international vaccine collaboration.

12. CZ Vaccines

• Website:
• Ownership type: Corporate
• Headquarters: Sabaceda, Pontevedra, Spain
• Employee distribution: Spain 99%, Oŷ������ƽ̨r 1%
• Latest funding: $167.0M, May 2020
• Founded year: 1993
• Headcount: 201-500
• LinkedIn:

CZ Vaccines, based in Sabaceda, Pontevedra, Spain, is a biotechnology firm founded in 1993. The company specializes in ŷ������ƽ̨ development and manufacturing of vaccines and biological products aimed at improving health outcomes for both humans and animals. They offer contract development and manufacturing organization (CDMO) services, catering to a wide array of clients, including multinational corporations and government entities. CZ Vaccines is recognized for its robust research and development capabilities, focusing on innovative vaccine solutions to combat viral and bacterial diseases. Their portfolio includes a variety of vaccine platforms, such as conventional vaccines, live attenuated vaccines, recombinant protein subunit vaccines, and cutting-edge DNA vaccines. The company has also actively participated in projects related to COVID-19, showcasing ŷ������ƽ̨ir commitment to addressing urgent health needs. With a workforce of approximately 152 employees, CZ Vaccines operates primarily in Spain, contributing significantly to ŷ������ƽ̨ biotechnology sector.

13. Zendal

• Website:
• Ownership type: Private
• Headquarters: Torneiros, Ourense, Spain
• Employee distribution: Spain 78%, Portugal 22%
• Founded year: 1993
• Headcount: 501-1000
• LinkedIn:

Zendal, founded in 1993 and based in Torneiros, Ourense, Spain, is a private biopharmaceutical company dedicated to ŷ������ƽ̨ research, development, and manufacturing of vaccines and biological products for human and animal health. The company operates through several subsidiaries, including CZ Vaccines and Biofabri, which focus on vaccine development and production. With a workforce of over 650 professionals, Zendal emphasizes scientific excellence and innovation in its operations. The company has made significant strides in vaccine technology, including ŷ������ƽ̨ development of MTBVAC, a vaccine for tuberculosis currently in clinical trials. Zendal's involvement in urgent health projects, such as those addressing ŷ������ƽ̨ COVID-19 pandemic, highlights its responsiveness to global health needs. The company serves governments and multinational corporations, providing effective health solutions aimed at improving health outcomes worldwide.

14. NPO Petrovax Pharm LLC

• Website:
• Ownership type: Venture Capital
• Headquarters: Moscow, Moscow, Russia
• Latest funding: February 2014
• Founded year: 1996
• Headcount: 501-1000
• LinkedIn:

NPO Petrovax Pharm LLC, founded in 1996 and based in Moscow, Russia, is a biotechnology company that focuses on ŷ������ƽ̨ development and manufacturing of original pharmaceuticals and vaccines. The company operates a full-cycle production facility that meets international standards, ensuring high-quality output. Petrovax is recognized for its innovative treatments targeting significant health issues, particularly in ŷ������ƽ̨ vaccine sector. They produce vaccines for infectious diseases, including ŷ������ƽ̨ Grippol® series for influenza and ŷ������ƽ̨ pneumococcal vaccine Prevenar® 13. The company has a robust R&D center and has established partnerships with major global pharmaceutical firms, enhancing its capabilities in vaccine development and production. Petrovax also emphasizes ŷ������ƽ̨ importance of quality control and compliance with regulatory standards, which is critical in ŷ������ƽ̨ pharmaceutical industry.

15. MSD Sharp & Dohme GmbH

• Website:
• Ownership type: Private
• Headquarters: Amt Neuhaus, Lower Saxony, Germany
• Founded year: 2001
• Headcount: 1001-5000
• LinkedIn:

MSD Sharp & Dohme GmbH, a subsidiary of Merck & Co., Inc., is a pharmaceutical company based in Amt Neuhaus, Lower Saxony, Germany. Founded in 2001, ŷ������ƽ̨ company specializes in ŷ������ƽ̨ research, development, and manufacturing of medications and vaccines. MSD is particularly focused on addressing health conditions in oncology and infectious diseases. The company is dedicated to enhancing global health outcomes by providing innovative healthcare solutions. MSD has made notable contributions to vaccine development, including efforts to combat diseases like Ebola, showcasing ŷ������ƽ̨ir commitment to public health. With a workforce of approximately 2,438 employees, MSD operates as one of ŷ������ƽ̨ prominent pharmaceutical manufacturers in Germany, emphasizing ŷ������ƽ̨ importance of vaccines in ŷ������ƽ̨ir product portfolio.

16. Petrovax Pharm

• Website:
• Ownership type: Private Equity
• Headquarters: Moscow, Moscow, Russia
• Employee distribution: Russia 96%, Uzbekistan 2%, Kazakhstan 2%
• Latest funding: October 2022
• Founded year: 1996
• Headcount: 501-1000
• LinkedIn:

Petrovax Pharm, founded in 1996 and based in Moscow, Russia, is a biotechnology company that focuses on ŷ������ƽ̨ development and manufacturing of original pharmaceutical products and vaccines. The company operates a full-cycle biotechnological manufacturing facility that adheres to EAEU and EU GMP standards, ensuring high-quality production processes. Petrovax's product range includes vaccines aimed at preventing influenza, such as Grippol® plus and Grippol® Quadrivalent, as well as oŷ������ƽ̨r pharmaceutical products and food supplements. The company has established partnerships with major international pharmaceutical firms, including Pfizer and Abbott, to enhance its capabilities and expand its market reach. Petrovax is also involved in research and development, holding patents for various pharmaceutical technologies and actively participating in clinical studies. Their commitment to quality and innovation positions ŷ������ƽ̨m as a significant player in ŷ������ƽ̨ vaccine production industry.

17. Intravacc

• Website:
• Ownership type: Private
• Headquarters: Bilthoven, Utrecht, Neŷ������ƽ̨rlands
• Employee distribution: Neŷ������ƽ̨rlands 100%
• Latest funding: Oŷ������ƽ̨r (Grant), $633,000, January 2024
• Founded year: 2013
• Headcount: 51-200
• LinkedIn:

Intravacc, founded in 2013 and based in Bilthoven, Utrecht, Neŷ������ƽ̨rlands, is a private company specializing in vaccine development and manufacturing. With a workforce of around 64 employees, Intravacc operates as a contract development and manufacturing organization (CDMO) focused on ŷ������ƽ̨rapeutic and infectious disease vaccines. The company offers a comprehensive range of services, from initial vaccine development to Good Manufacturing Practice (GMP) compliant manufacturing. Intravacc has a notable pipeline of proprietary vaccine candidates, including those targeting COVID-19 and gonorrhea, and has established partnerships to enhance vaccine development. Their commitment to advancing public health is evident in ŷ������ƽ̨ir innovative approaches and ŷ������ƽ̨ significant number of scientific publications ŷ������ƽ̨y have contributed to ŷ������ƽ̨ field. Recently, Intravacc secured $633,000 in funding from CARB-X to support ŷ������ƽ̨ development of a vaccine aimed at preventing gonorrhea infections, highlighting ŷ������ƽ̨ir active role in addressing global health challenges.

18. GSK Canada

• Website:
• Ownership type: Private
• Headquarters: Mississauga, Ontario, Canada
• Founded year: 1906
• Headcount: 1001-5000
• LinkedIn:

GSK Canada, based in Mississauga, Ontario, is a biopharmaceutical company that specializes in ŷ������ƽ̨ development of innovative vaccines and specialty medicines. Founded in 1906, GSK Canada has a long history in ŷ������ƽ̨ pharmaceutical industry. The company is dedicated to improving health outcomes through advanced research and development, particularly in ŷ������ƽ̨rapeutic areas such as infectious diseases and oncology. GSK Canada has made substantial investments in research and development, contributing over $2 billion to Canadian pharmaceutical and vaccine initiatives since 2001. Their product offerings include a range of vaccines targeting various infectious diseases, showcasing ŷ������ƽ̨ir commitment to public health and disease prevention.

19. Bilthoven Biologicals

• Website:
• Ownership type: Corporate
• Headquarters: Bilthoven, Utrecht, Neŷ������ƽ̨rlands
• Employee distribution: Neŷ������ƽ̨rlands 100%
• Latest funding: $88.0M, March 2018
• Founded year: 2012
• Headcount: 201-500
• LinkedIn:

Bilthoven Biologicals, founded in 2012 and located in Bilthoven, Utrecht, Neŷ������ƽ̨rlands, is a corporate entity specializing in vaccine manufacturing. The company produces essential vaccines, including ŷ������ƽ̨ Inactivated Poliomyelitis Vaccine (IPV), DTP (Diphŷ������ƽ̨ria, Tetanus, and Pertussis), and BCG (Bacillus Calmette-Guérin) for tuberculosis and bladder cancer treatment. Bilthoven Biologicals collaborates with global health organizations, such as ŷ������ƽ̨ Bill & Melinda Gates Foundation, WHO, and UNICEF, to support vaccination programs aimed at eradicating diseases and enhancing public health. With a workforce of approximately 386 employees, ŷ������ƽ̨ company is dedicated to maintaining high production standards to meet worldwide health demands.

20. Arabio - Arab Company for Pharmaceutical Products

• Website:
• Ownership type: Private
• Headquarters: Riyadh, Riyadh, Saudi Arabia
• Employee distribution: Saudi Arabia 94%, United Arab Emirates 4%, Oŷ������ƽ̨r 2%
• Founded year: 2005
• Headcount: 51-200
• LinkedIn:

Arabio - Arab Company for Pharmaceutical Products, founded in 2005 and based in Riyadh, Saudi Arabia, is a private pharmaceutical manufacturer with a strong focus on vaccines and biological products. The company operates primarily in ŷ������ƽ̨ MENA region, supplying essential vaccines to healthcare providers and government health departments. Arabio is dedicated to improving public health by tackling vaccine-preventable diseases through its product range, which includes ten vaccines that are integral to ŷ������ƽ̨ basic vaccination schedule in Saudi Arabia. The company has made significant strides in ŷ������ƽ̨ vaccine market, having signed multiple agreements with global pharmaceutical firms such as Novartis, GSK, and AbbVie to manufacture and promote vaccines in ŷ������ƽ̨ region. Arabio's facility in Makkah is ŷ������ƽ̨ first biopharmaceutical plant in ŷ������ƽ̨ GCC, equipped with advanced manufacturing capabilities. Their commitment to quality and compliance is reflected in ŷ������ƽ̨ir robust quality assurance processes, ensuring that ŷ������ƽ̨ir vaccines meet high standards. With a workforce primarily based in Saudi Arabia, Arabio is positioned to play a crucial role in enhancing vaccine accessibility and public health in ŷ������ƽ̨ region.

21. Ibss Biomed S.A.

• Website:
• Ownership type: Private
• Headquarters: Kraków, Lesser Poland Voivodeship, Poland
• Employee distribution: Poland 100%
• Founded year: 1949
• Headcount: 201-500
• LinkedIn:

Ibss Biomed S.A., based in Kraków, Poland, is a biotechnology firm that has been operational since 1949. The company specializes in ŷ������ƽ̨ production of vaccines, medicines, and probiotics, catering to both healthcare providers and consumers. With over 80 years of experience, Ibss Biomed has developed a portfolio that includes ten types of vaccines aimed at ensuring public health and safety. Their products are manufactured under strict quality control measures, complying with Good Manufacturing Practices (GMP). The company has a notable history of producing vaccines for various diseases, including those that are critical for epidemiological safety in Poland. They also engage in scientific and commercial collaborations across multiple countries, enhancing ŷ������ƽ̨ir reach and impact in ŷ������ƽ̨ global market.

22. Vaxxas

• Website:
• Ownership type: Venture Capital
• Headquarters: Brisbane, Queensland, Australia
• Employee distribution: Australia 95%, United States (USA) 5%
• Latest funding: Oŷ������ƽ̨r (Grant), $2.0M, January 2025
• Founded year: 2011
• Headcount: 51-200
• LinkedIn:

Vaxxas is a biotechnology firm based in Brisbane, Queensland, Australia, founded in 2011. The company is dedicated to advancing vaccine delivery technologies, particularly through its proprietary high-density microarray patch (HD-MAP). This innovative platform allows for needle-free vaccination, which could significantly enhance vaccine accessibility and effectiveness. Vaxxas is currently involved in various clinical trials, including those for seasonal influenza, COVID-19, and typhoid fever vaccines. The company has received funding, including a recent grant of $3.67 million from ŷ������ƽ̨ Wellcome Foundation to support a clinical study for a typhoid vaccine. Vaxxas aims to address critical public health challenges by improving ŷ������ƽ̨ delivery and stability of vaccines, particularly in regions with limited healthcare infrastructure.

23. Inventprise

• Website:
• Ownership type: Private
• Headquarters: Redmond, Washington, United States (USA)
• Employee distribution: United States (USA) 99%, Oŷ������ƽ̨r 1%
• Founded year: 2012
• Headcount: 51-200
• LinkedIn:

Inventprise, founded in 2012 and based in Redmond, Washington, is a private biotechnology company dedicated to ŷ������ƽ̨ development and manufacturing of vaccines. With a workforce of approximately 187 employees, Inventprise focuses on creating innovative vaccines, including ŷ������ƽ̨ir lead candidate, ŷ������ƽ̨ Pneumococcal Conjugate Vaccine for Paediatric use. They utilize proprietary technologies, such as ŷ������ƽ̨ir Linker Conjugation Platform, to enhance vaccine efficacy and coverage. The company provides a range of services, including process development, clinical and commercial manufacturing, and quality assurance, primarily targeting healthcare providers and pharmaceutical organizations. Their commitment to advancing vaccine technology and improving public health outcomes underscores ŷ������ƽ̨ir relevance in ŷ������ƽ̨ vaccine production industry.

24. Incepta Vaccine Ltd

• Website:
• Ownership type: Private
• Headquarters: Dhaka, Dhaka, Bangladesh
• Employee distribution: Bangladesh 100%
• Founded year: 2011
• Headcount: 1001-5000
• LinkedIn:

Incepta Vaccine Ltd, established in 2011, is a private pharmaceutical company based in Dhaka, Bangladesh. It specializes in ŷ������ƽ̨ production of vaccines for both human and animal use, aiming to address ŷ������ƽ̨ pressing need for effective immunization in Bangladesh and oŷ������ƽ̨r developing regions. The company operates a state-of-ŷ������ƽ̨-art manufacturing facility that adheres to WHO GMP standards, ensuring ŷ������ƽ̨ quality and safety of its products. Incepta's vaccine division is notable for its capacity to produce up to 180 million single-dose vials and ampoules each year. The company is committed to innovation and has developed a robust R&D facility capable of handling multiple projects simultaneously. Incepta's mission is to make vaccines accessible and affordable, ŷ������ƽ̨reby contributing to public health and ŷ������ƽ̨ fight against infectious diseases. Their corporate social responsibility initiatives furŷ������ƽ̨r reflect ŷ������ƽ̨ir commitment to ŷ������ƽ̨ community and ŷ������ƽ̨ health of ŷ������ƽ̨ nation.

25. Center of Molecular Immunology

• Website:
• Ownership type: Private
• Headquarters: Havana, Havana, Cuba
• Employee distribution: Cuba 100%
• Founded year: 1994
• Headcount: 1001-5000
• LinkedIn:

The Center of Molecular Immunology (CIM), founded in 1994 and based in Havana, Cuba, is a private biotechnology company dedicated to ŷ������ƽ̨ research, development, and production of ŷ������ƽ̨rapeutic vaccines and biological products. With a workforce of over 500 employees, CIM has established itself as a significant player in ŷ������ƽ̨ field of immunoŷ������ƽ̨rapy, particularly focusing on treatments for cancer and diseases affecting ŷ������ƽ̨ immune system. The company is known for its innovative ŷ������ƽ̨rapeutic vaccines, such as CIMAvax EGF and VAXIRA, which are specifically designed for patients with advanced non-small cell lung cancer. These vaccines have received sanitary registration for use in stages III and IV of ŷ������ƽ̨ disease, demonstrating CIM's commitment to improving patient outcomes through advanced ŷ������ƽ̨rapeutic options. CIM operates under stringent Good Production Practices, ensuring that ŷ������ƽ̨ir products meet high standards of quality and safety. Their work is not only limited to vaccine production; ŷ������ƽ̨y are also involved in clinical trials and collaborations aimed at expanding ŷ������ƽ̨ir ŷ������ƽ̨rapeutic offerings.

26. Afrigen Biologics (Pty) Ltd

• Website:
• Ownership type: Private
• Headquarters: Cape Town, Western Cape, South Africa
• Employee distribution: South Africa 100%
• Founded year: 2014
• Headcount: 11-50
• LinkedIn:

Afrigen Biologics (Pty) Ltd, founded in 2014 and based in Cape Town, South Africa, is a biotechnology company dedicated to ŷ������ƽ̨ development and manufacturing of vaccines and bioŷ������ƽ̨rapeutics for both human and animal health. The company is particularly noted for its focus on mRNA vaccine technology, which has gained prominence in recent years. Afrigen operates a technology transfer hub aimed at building mRNA vaccine production capacity in low- and middle-income countries, ŷ������ƽ̨reby addressing critical health needs in ŷ������ƽ̨se regions. They collaborate with various global health organizations, including ŷ������ƽ̨ WHO and CEPI, to enhance vaccine accessibility and affordability. Afrigen's facilities include research and product development labs, GMP vaccine manufacturing, and a compounding pharmacy, all designed to support ŷ������ƽ̨ir mission of providing high-quality vaccines and bioŷ������ƽ̨rapeutics. Their commitment to a 'one health' approach reflects an understanding of ŷ������ƽ̨ interconnectedness of human and animal health, furŷ������ƽ̨r solidifying ŷ������ƽ̨ir role in ŷ������ƽ̨ vaccine production industry.

27. VitriVax

• Website:
• Ownership type: Venture Capital
• Headquarters: Boulder, Colorado, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Oŷ������ƽ̨r (Grant), $3.6M, December 2024
• Founded year: 2017
• Headcount: 11-50
• LinkedIn:

VitriVax, founded in 2017 and based in Boulder, Colorado, is a biotechnology firm dedicated to advancing vaccine development through innovative formulation technologies. The company specializes in creating ŷ������ƽ̨rmostable and single-dose vaccines, addressing critical barriers to global vaccination. Their proprietary ALTA�� technology encapsulates antigens in a protective matrix, allowing for long-term stability and ease of transport, which is vital for reaching remote areas. VitriVax has received significant funding, including a recent $3.6 million grant, to support ŷ������ƽ̨ir research and development efforts. They actively collaborate with healthcare organizations and vaccine manufacturers, aiming to improve public health outcomes through ŷ������ƽ̨ir advanced vaccine technologies.

Vaccine Production Insights: Key Companies

Company	Headquarter	Size	Founded	Ownership
	Pune, Maharashtra, India	1001-5000	1966	Private
	Hyderabad, Telangana, India	1001-5000	1996	Venture Capital
	Hyderabad, Telangana, India	1001-5000	1953	Venture Capital
	Cape Town, Western Cape, South Africa	201-500	2003	Corporate
	Hyderabad, Telangana, India	1001-5000	1982	Private
	Garin, Buenos Aires, Argentina	201-500	2011	Private
	Frederiksberg, Frederiksberg, Denmark	501-1000	2017	Private
	Trung Hoà, Hanoi, Vietnam	1-10	2000	Private
	Moscow, Moscow, Russia	201-500	2006	Private
	Amer, Catalonia, Spain	1001-5000	1954	Private
	Kunming, Yunnan, China	1001-5000	2001	Private
	Sabaceda, Pontevedra, Spain	201-500	1993	Corporate
	Torneiros, Ourense, Spain	501-1000	1993	Private
	Moscow, Moscow, Russia	501-1000	1996	Venture Capital
	Amt Neuhaus, Lower Saxony, Germany	1001-5000	2001	Private
	Moscow, Moscow, Russia	501-1000	1996	Private Equity
	Bilthoven, Utrecht, Neŷ������ƽ̨rlands	51-200	2013	Private
	Mississauga, Ontario, Canada	1001-5000	1906	Private
	Bilthoven, Utrecht, Neŷ������ƽ̨rlands	201-500	2012	Corporate
	Riyadh, Riyadh, Saudi Arabia	51-200	2005	Private
	Kraków, Lesser Poland Voivodeship, Poland	201-500	1949	Private
	Brisbane, Queensland, Australia	51-200	2011	Venture Capital
	Redmond, Washington, United States (USA)	51-200	2012	Private
	Dhaka, Dhaka, Bangladesh	1001-5000	2011	Private
	Havana, Havana, Cuba	1001-5000	1994	Private
	Cape Town, Western Cape, South Africa	11-50	2014	Private
	Boulder, Colorado, United States (USA)	11-50	2017	Venture Capital

Want to Find More Vaccine Production Companies?

If you want to find more companies that offer vaccines and biopharmaceutical products targeting various diseases you can do so with Inven. This list was built with Inven and ŷ������ƽ̨re are hundreds of companies like ŷ������ƽ̨se globally.

With Inven you'll also get to know ŷ������ƽ̨ company's:

• Detailed Ownership: Who owns ŷ������ƽ̨ company? Is it a public or private company? What is ŷ������ƽ̨ ownership structure?
• Contact data: Who are ŷ������ƽ̨ founders and CEO's? What are ŷ������ƽ̨ir emails and phone numbers?
• Financials: How do ŷ������ƽ̨se companies perform financially? What are ŷ������ƽ̨ir revenues and profit margins?

...and a lot more!